Bloomberg – Drugmakers are getting more and more nervous that hedge funds have found a way to make money by putting their patents in jeopardy.
Taking advantage of new rules created by Congress three years ago, hedge funds have increasingly been filing challenges to pharmaceutical patents. Some may be angling for payouts to drop their claims, while others are shorting the stock, betting that the manufacturers’ shares will plummet.
